Open Access Open Access  Restricted Access Subscription or Fee Access

Chronology of Lipid Science and Disorders with Reference to Recent Advancement in its Management: A Review

Mohammad Anas, Tanzeel Ahmad, Mohd. Anwar, Jamal Azmat


The study of modern lipid began in the 17th and 18th centuries. The 19th century chemist, Chevreul, identified several fatty acids, suggested the name ‘cholesterine’ for the fatty substance in gallstones, coined the word ‘glycerine’, and showed that fats were comprised of glycerol and fatty acids. The 20th century brought many advances in the understanding of lipoprotein structure and function, and explored relationships between lipoproteins and disease states. It has been long known that lipid abnormalities are major risk factors for coronary artery diseases. The lipids are a heterogeneous group of compounds, including fats, oils, steroids, waxes and related compounds that are related more by their physical than by their chemical properties. Lipids are important dietary constituents not only because of their high energy value, but also because of the fat-soluble vitamins and the essential fatty acids contained in the fat of natural foods. This paper is aimed at to arrange a chronology of lipid science with recent advancement.


Lipid, coronary artery diseases, fatty acids

Full Text:



Smith, Oxford dictionary of biochemistry and molecular biology, 2nd Edn. Oxford university press, Oxford (UK) (2000).

Raju S.M., Raju B., Illustrated Medical Biochemistry, Jaypee Brothers Medical Publishers (P) Ltd., New Delhi, 2010; P: 85–96

Weatherall D. J., Ledingham J. G. G. and Warrell D. A., Oxford Textbook of Medicine, Oxford University Press,1985; P: 9.60–9.69.

A brief history of lipid and lipoprotein measurements and their contribution to clinical chemistry McNamara JR Warnick GR, Cooper GR. Clin Chim Acta. 2006 Jul 23;369(2):158–67. Epub 2006 Mar 24

Steinberg, D., 2006. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversy. Journal of lipid research, 47(7), pp.1339–1351.

Murphy, D.J., 2005. The study and utilization of plant lipids: from margarine to lipid rafts. Plant Lipids: Biology, Utilisation and Manipulation, pp.1–26.

Olson, R.E., 1998. Evolution of ideas about the nutritional value of dietary fat: introduction. The Journal of nutrition, 128(2), pp.421S-422S..

Pacifici, R., 1993. The power of negative thinking. BR Bloom Preventing antiphospholipid antibody.-induced fetal loss: a new idea. MD Lockshin Vitamin K nutrition and postmenopausal osteoporosis. The Journal of Clinical Investigation, 91(4).

Hayden MR, Tyagi SC. Vasa vasorum in plaque angiogenesis, metabolic syndrome, type 2 Diabetes mellitus, and atheroscleropathy: a malignant transformation. Cardiovascular Diabetology. 2004 Feb; 3(1): 1–16.

Hayden MR, Tyagi SC. Vasa vasorum in plaque angiogenesis, metabolic syndrome, type 2 Diabetes mellitus, and atheroscleropathy: a malignant transformation. Cardiovascular Diabetology. 2004 Feb; 3(1): 1–16.

Gofman J.W., Lindgren F.T., Elliott H., Ultracentrifugal studies of lipoproteins of human serum, J Biol Chem, 1949; P: 973–979.

NCEP III. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001; Vol: 285, P: 2486–2497.

Gotto Antonio M., Evolving concept of dyslipidemia, atherosclerosis, and cardiovascular disease, JACC, 2005; Vol: 46, P: 1219–1224.

Kapur N. K., Ashen D. and Blumenthal R. S., High density lipoprotein cholesterol: an evolving target of therapy in management of cardiovascular disease, Vascular Health and Risk Management, 2008; Vol: 4(1), P: 39–57.

Bays, H.E., Jones, P.H., Brown, W.V. and Jacobson, T.A., 2014. National Lipid Association annual summary of clinical lipidology 2015. Journal of clinical lipidology, 8(6), pp.S1-S36.

Schachter, M., 2005. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundamental & clinical pharmacology, 19(1), pp.117–125.

Stone, N.J., Robinson, J.G., Lichtenstein, A.H., Merz, C.N.B., Blum, C.B., Eckel, R.H., Goldberg, A.C., Gordon, D., Levy, D., Lloyd-Jones, D.M. and McBride, P., 2014. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 63(25 Part B), pp.2889–2934.

Benjamin, E.J., Blaha, M.J., Chiuve, S.E., Cushman, M., Das, S.R., Deo, R., Floyd, J., Fornage, M., Gillespie, C., Isasi, C.R. and Jiménez, M.C., 2017. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation, 135(10), pp.e146-e603.

Jellinger, P.S., Handelsman, Y., Rosenblit, P.D., Bloomgarden, Z.T., Fonseca, V.A., Garber, A.J., Grunberger, G., Guerin, C.K., Bell, D.S., Mechanick, J.I. and Pessah-Pollack, R., 2017. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocrine Practice, 23(s2), pp.1–87.


  • There are currently no refbacks.